Blume Capital Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-100
| Closed | -$22.8K | – | 338 |
|
|
2025
Q4 | $22.8K | Hold |
100
| – | – | ﹤0.01% | 224 |
|
|
2025
Q3 | $23.2K | Sell |
100
-68
| -40% | -$13.8K | ﹤0.01% | 232 |
|
|
2025
Q2 | $31.2K | Buy |
168
+12
| +8% | +$2.23K | 0.01% | 214 |
|
|
2025
Q1 | $32.7K | Buy |
156
+6
| +4% | +$1.17K | 0.01% | 206 |
|
|
2024
Q4 | $26.7K | Sell |
150
-70
| -32% | -$12.9K | 0.01% | 212 |
|
|
2024
Q3 | $43.4K | Buy |
+220
| New | +$41.1K | 0.01% | 193 |
|
|
2023
Q1 | – | Sell |
-150
| Closed | -$24.2K | – | 315 |
|
|
2022
Q4 | $24.2K | Hold |
150
| – | – | 0.01% | 202 |
|
|
2022
Q3 | $20K | Hold |
150
| – | – | 0.01% | 203 |
|
|
2022
Q2 | $23K | Sell |
150
-32
| -18% | -$4.89K | 0.01% | 199 |
|
|
2022
Q1 | $30K | Hold |
182
| – | – | 0.01% | 187 |
|
|
2021
Q4 | $25K | Hold |
182
| – | – | 0.01% | 213 |
|
|
2021
Q3 | $20K | Hold |
182
| – | – | 0.01% | 228 |
|
|
2021
Q2 | $21K | Hold |
182
| – | – | 0.01% | 217 |
|
|
2021
Q1 | $20K | Sell |
182
-100
| -35% | -$10.7K | 0.01% | 201 |
|
|
2020
Q4 | $30K | Hold |
282
| – | – | 0.01% | 138 |
|
|
2020
Q3 | $25K | Sell |
282
-32
| -10% | -$3.01K | 0.01% | 139 |
|
|
2020
Q2 | $31K | Buy |
314
+64
| +26% | +$5.63K | 0.02% | 132 |
|
|
2020
Q1 | $19K | Hold |
250
| – | – | 0.01% | 147 |
|
|
2019
Q4 | $22K | Hold |
250
| – | – | 0.01% | 157 |
|
|
2019
Q3 | $18K | Sell |
250
-400
| -62% | -$27.4K | 0.01% | 162 |
|
|
2019
Q2 | $47K | Hold |
650
| – | – | 0.02% | 120 |
|
|
2019
Q1 | $52K | Sell |
650
-100
| -13% | -$8.18K | 0.03% | 123 |
|
|
2018
Q4 | $69K | Hold |
750
| – | – | 0.04% | 109 |
|
|
2018
Q3 | $71K | Hold |
750
| – | – | 0.04% | 99 |
|
|
2018
Q2 | $69K | Hold |
750
| – | – | 0.04% | 95 |
|
|
2018
Q1 | $70K | Sell |
750
-325
| -30% | -$35.7K | 0.04% | 99 |
|
|
2017
Q4 | $104K | Sell |
1,075
-100
| -9% | -$9.43K | 0.05% | 86 |
|
|
2017
Q3 | $104K | Buy |
1,175
+675
| +135% | +$51.4K | 0.06% | 79 |
|
|
2017
Q2 | $36K | Sell |
500
-117
| -19% | -$7.87K | 0.02% | 117 |
|
|
2017
Q1 | $40K | Hold |
617
| – | – | 0.02% | 110 |
|
|
2016
Q4 | $39K | Buy |
617
+407
| +194% | +$24.8K | 0.02% | 113 |
|
|
2016
Q3 | $13K | Buy |
+210
| New | +$13.6K | 0.01% | 143 |
|
|
2015
Q1 | – | Sell |
-1,000
| Closed | -$65K | – | 285 |
|
|
2014
Q4 | $65K | Buy |
+1,000
| New | +$63K | 0.05% | 117 |
|
Other funds holding ABBV
VCM
VPM
Blume Capital Management's ABBV Position: Q1 2026 in Review
Blume Capital Management sold out of AbbVie (ABBV) in Q1 2026, closing a stake of 100 shares — an estimated $22.8K sold.
Blume Capital Management first reported a position in ABBV in Q4 2014 and held it in 33 quarters. The position peaked at $104K in Q4 2017. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Blume Capital Management reported no remaining AbbVie position as of Q1 2026 after selling out during the quarter.
- Blume Capital Management sold 100 AbbVie shares in Q1 2026, an estimated $22.8K.
- Blume Capital Management first reported a position in AbbVie in Q4 2014 and held it in 33 quarters.
- Blume Capital Management's AbbVie position peaked at $104K in Q4 2017.
- 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Blume Capital Management's 13F filing for Q1 2026, filed 1 May 2026.